Targeted deletion of Vglut2 expression in the embryonal telencephalon promotes an anxiolytic phenoty Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=iups20 Upsala Journal of Medical Sciences ISSN: 0300-9734 (Print) 2000-1967 (Online) Journal homepage: https://www.tandfonline.com/loi/iups20 Targeted deletion of Vglut2 expression in the embryonal telencephalon promotes an anxiolytic phenotype of the adult mouse Karin Nordenankar, Assar Bergfors & Åsa Wallén-Mackenzie To cite this article: Karin Nordenankar, Assar Bergfors & Åsa Wallén-Mackenzie (2015) Targeted deletion of Vglut2 expression in the embryonal telencephalon promotes an anxiolytic phenotype of the adult mouse, Upsala Journal of Medical Sciences, 120:3, 144-156, DOI: 10.3109/03009734.2015.1032454 To link to this article: https://doi.org/10.3109/03009734.2015.1032454 © Informa Healthcare View supplementary material Published online: 09 Apr 2015. Submit your article to this journal Article views: 585 View related articles View Crossmark data Citing articles: 1 View citing articles https://www.tandfonline.com/action/journalInformation?journalCode=iups20 https://www.tandfonline.com/loi/iups20 https://www.tandfonline.com/action/showCitFormats?doi=10.3109/03009734.2015.1032454 https://doi.org/10.3109/03009734.2015.1032454 https://www.tandfonline.com/doi/suppl/10.3109/03009734.2015.1032454 https://www.tandfonline.com/doi/suppl/10.3109/03009734.2015.1032454 https://www.tandfonline.com/action/authorSubmission?journalCode=iups20&show=instructions https://www.tandfonline.com/action/authorSubmission?journalCode=iups20&show=instructions https://www.tandfonline.com/doi/mlt/10.3109/03009734.2015.1032454 https://www.tandfonline.com/doi/mlt/10.3109/03009734.2015.1032454 http://crossmark.crossref.org/dialog/?doi=10.3109/03009734.2015.1032454&domain=pdf&date_stamp=2015-04-09 http://crossmark.crossref.org/dialog/?doi=10.3109/03009734.2015.1032454&domain=pdf&date_stamp=2015-04-09 https://www.tandfonline.com/doi/citedby/10.3109/03009734.2015.1032454#tabModule https://www.tandfonline.com/doi/citedby/10.3109/03009734.2015.1032454#tabModule Upsala Journal of Medical Sciences. 2015; 120: 144–156 ORIGINAL ARTICLE Targeted deletion of Vglut2 expression in the embryonal telencephalon promotes an anxiolytic phenotype of the adult mouse KARIN NORDENANKAR, ASSAR BERGFORS & ÅSA WALLÉN-MACKENZIE Department of Neuroscience, Unit of Functional Neurobiology and Unit of Developmental Genetics, Uppsala University, Box 593, S-75214 Uppsala, Sweden Abstract Background. Anxiety is a natural emotion experienced by all individuals. However, when anxiety becomes excessive, it contributes to the substantial group of anxiety disorders that affect one in three people and thus are among the most common psychiatric disorders. Anxiolysis, the reduction of anxiety, is mediated via several large groups of therapeutical compounds, but the relief is often only temporary, and increased knowledge of the neurobiology underlying anxiety is needed in order to improve future therapies. Aim. We previously demonstrated that mice lacking forebrain expression of the Vesicular glutamate transporter 2 (Vglut2) from adolescence showed a strong anxiolytic behaviour as adults. In the current study, we wished to analyse if removal of Vglut2 expression already from mid-gestation of the mouse embryo would give rise to similar anxiolysis in the adult mouse. Methods. We produced transgenic mice lacking Vglut2 from mid-gestation and analysed their affective behaviour, including anxiety, when they had reached adulthood. Results. The transgenic mice lacking Vglut2 expression from mid-gestation showed certain signs of anxiolytic behaviour, but this phenotype was not as prominent as when Vglut2 was removed during adolescence. Conclusion. Our results suggest that both embryonal and adolescent forebrain expression of Vglut2 normally contributes to balancing the level of anxiety. As the neurobiological basis for anxiety is similar across species, our results in mice may help improve the current understanding of the neurocircuitry of anxiety, and hence anxiolysis, also in humans. Key words: Affective, anxiolysis, behaviour, development, psychostimulant Introduction Glutamate is the main excitatory neurotransmitter in the mammalian brain, and glutamatergic transmission is solidly regulated both pre-and post-synaptically during healthy conditions. Dysregulated glutamater- gic transmission is implicated in several neuropsychi- atric disorders, including schizophrenia, addiction and anxiety disorders (for examples of recent reviews see (1-4)). Better understanding of the neurobiology and neurocircuitry of glutamatergic neurons is therefore needed to identify future potential thera- peutic targets. The presence of vesicular glutamate transporters (VGLUTs) 1 and/or 2 (encoded by the Vglut1 and Vglut2 genes, aka Slc17A7 and Slc17A6, respectively) defines the presynaptic glutamate site (5-10). Expres- sion analyses of the adult telencephalic area in the mouse and rat have shown a strong predominance for Vglut1 mRNA across the cerebral cortex and hippo- campus, areas in which Vglut2 is only found regionally distributed. More specifically, Vglut2 mRNA is Correspondence: Åsa Wallén-Mackenzie, Department of Neuroscience, Unit of Functional Neurobiology and Unit of Developmental Genetics, Uppsala University, Box 593, 751 24 Uppsala, Sweden. Fax: +46 18 511 540. E-mail: asa.mackenzie@neuro.uu.se (Received 15 January 2015; accepted 13 March 2015) This is an open-access article distributed under the terms of the CC-BY-NC-ND 3.0 License which permits users to download and share the article for non- commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is credited. ISSN 0300-9734 print/ISSN 2000-1967 online � 2015 Informa Healthcare DOI: 10.3109/03009734.2015.1032454 http://informahealthcare.com/journal/ups mailto:asa.mackenzie@neuro.uu.se localized to the retrosplenial group (RSG), layers III and V/VI of the neocortex, and to the endo-piriform cortex. Within the hippocampal formation, the expression is confined to the subiculum (7,9,11-13). Both Vglut1 and Vglut2 mRNAs are found in the olfactory bulb (14), and both are local- ized to the amygdaloid complex, albeit to different subpopulations. Vglut2 mRNA is detected only in the medial (Me), anterior cortical (ACo), and anterior basomedial (BM) nuclei, while Vglut1 mRNA is found in all other amygdaloid populations (13,15). Vglut2, the predominant Vglut in deep structures of the adult brain, is broadly distributed already at mid- gestation of the developing mouse embryo (16,17). This expression is subsequently down-regulated in most areas postnatally populated by Vglut1 mRNA (7-9,18-20). Behavioural phenotyping of mice gene-targeted for either Vglut1 or Vglut2 has implied a role for the presynaptic glutamate site in behaviour of relevance for psychiatric conditions. Mice heterozygous for Vglut1, the predominant Vglut in the telencephalon, showed an anxiogenic phenotype as well as depres- sion- and schizophrenia-related behaviours (21,22). Demonstrating the importance of Vglut2 in the brain- stem, a full knock-out of Vglut2 led to immediate neonatal lethality due to respiratory failure (23,24). By using the Cre/LoxP conditional gene targeting system (reviewed in (25)), the functional role of VGLUT2 in neuropsychiatric-like conditions has been further addressed. For example, several studies of mice gene-targeted specifically for Vglut2 within dopamine neurons (26) have demonstrated altera- tions in the response to psychostimulants, leading to a proposed role of VGLUT2 in mechanisms of importance for addiction (16,17,27-29). The regional distribution of Vglut2 in the forebrain was previously targeted in our laboratory at the adolescent stage by use of the CamKIIa-Cre transgenic mouse line, which can be detected from postnatal week 3 (30). By behavioural and biochemical analysis of adult Vglut2f/f;CaMKII-Cre conditional knock-out (cKO), we identified an anxiolytic phenotype alongside several behaviours relevant for animal models of schizophre- nia (13). In the current study, we aimed to approach whether Vglut2 gene expression during embryo devel- opment is of any relevance for affective behaviour at adulthood. To analyse this issue, we used the previ- ously described Emx1IRES-Cre knock-in mice (31) to drive dorsal telencephalic deletion of Vglut2 expres- sion from mid-gestation onwards. We analysed adult Vglut2f/f;Emx1-Cre cKO and control mice for functions of relevance to psychiatric conditions, including mea- sures of psychostimulant-induced behavioural activa- tion, sociability, and various aspects of anxiety. Material and methods Animals All mice used in the study were housed in the animal facility at the BMC, Uppsala University, in accor- dance with the Swedish regulation guidelines (Animal Welfare Act SFS 1998:56) and European Union legislation (Convention ETS123 and Directive 2010/63/EU). Ethical approval was obtained from the Uppsala Animal Ethical Committee. Mice were housed at constant temperature (21 ± 1�C) and humidity (50%–60%) with 2–8 mice per cage unless otherwise stated. All behavioural experiments took place during the light phase, between 06.00 and 18.00. Food (R3, Lactamin/Lantmännen, Sweden) and water were provided ad libitum unless otherwise stated. All behaviour tests were performed on adult (>10 weeks) mice. Generation of Vglut2f/f;Emx1-Cre mice The Vglut2f/f;Emx1-Cre mouse line was produced by using the breeding procedure established for condi- tional knock-out mice to ensure identical genetic back- ground (32). By crossing mice homozygous for the floxed allele of Vglut2 (Vglut2f/f) (24) with Emx1IRES-Cre knock-in mice (31), hereafter referred to as Emx1-Cre mice, both Vglut2f/f;Emx1-Cre(tg/wt) conditional knock-out mice (cKO) and Vglut2f/f;Emx1-Cre(wt/wt) control mice (which do not express the Emx1-Cre transgene and therefore have normal Vglut2 expression) were pro- duced as littermates which allows for behavioural phenotyping and comparison between genotype groups (33). The Vglut2f/f;Emx1-Cre cKO and ctrl mice were thus of the same genetic background, a mixture of C57/BL6 and Sv129. Genotyping was performed as previously described (24). Tissue sectioning and RNA probes Mice were intraepidermally injected with a 1:1 mix- ture of Dormitor (medetomidine hydrochloride, 70 mg/g body weight; Orion Pharma, Espoo, Finland) and Ketalar (ketamine hydrochloride, 7 mg/g body weight, Pfizer, Groton, CT, USA). Transcardial per- fusion was performed with phosphate-buffered saline (PBS) followed by 4% formaldehyde (HistoLab, Västra Frölunda, Sweden). The brain was excised and stored in 4% formaldehyde overnight, after which it was washed in PBS and embedded in 4% agarose and sectioned (70 mm) on a Leica VT1000S Vibra- tome (Leica Biosystems, Nussloch, Germany). Sections were dehydrated through a series of meth- anol washes (25%, 50%, and 75% methanol) and Deletion of Vglut2 expression in the embryonal telencephalon 145 lastly stored in 100% methanol at –20�C until further processing. Templates for in situ probes were derived from com- mercialcDNAclonesbyusinggene-specificpromotors (asdescribedatwww.genepaint.org).TheVglut2probe covers nucleotides (nts) 1616-2203 (NM_080853.2), the Vglut1 probe nts 462-1067 (NM_182993), and the vesicular inhibitory amino acid transporter (Viaat) probe nts 1578-1889 (NM_009508.1). The probes were synthesized by using T7, T3, or Sp6 RNA poly- merase in the presence of digoxigenin-11-UTP (Roche Diagnostics Scandinavia, Stockholm, Sweden). Probes were controlled and quantified by using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). In situ hybridization on free-floating sections Mouse brain sections were step-wise rehydrated from 100% methanol to PBT (PBS with 0.1% Tween-20 (Sigma-Aldrich Sweden AB, Stockholm, Sweden)) and bleached in 6% hydrogen peroxidase in PBT. Thereafter, the sections were permeabilized with 0.5% TritonX-100 (Sigma-Aldrich Sweden AB, Stockholm, Sweden), digested with 20 mg/mL pro- teinase K (Invitrogen, Nordic Biolabs, Täby, Sweden) and post-fixed in 4% formaldehyde (Histo- Lab) with PBT washes between all steps. Sections were then pre-hybridized at 55�C in hybridization buffer (50% formamide, 5 � SSC, pH 4.5, 1% SDS, 50 mg/mL of tRNA (Sigma), 50 mg/mL of heparin (Sigma), and PBT). The digoxigenin-labelled probe (1 mg/mL) diluted in hybridization buffer was heat-denatured at 80�C, cooled on ice, and added to the sections for hybridization overnight at 55�C (14– 16 h). Unbound probe was removed by sequential washes of buffer 1 (50% formamide, 5 � SSC, pH 4.5, and 1% SDS in PBT) followed by buffer 2 (50% formamide, 2 � SSC, pH 4.5, and 0.1% Tween-20 in PBT) at 55�C. The sections were further washed in 0.1% Tween-20 Tris-buffered saline (TBST) before incubation in blocking solution (1% blocking reagent (Roche Diagnostics Scandinavia, Stockholm, Swe- den)) together with 1:5,000 diluted anti-digoxigenin alkaline phosphates conjugated antibody (Roche Diagnostics Scandinavia) overnight at 4�C. Unbound antibodywasremovedby sequentialwashes with2mM levamisole (GTF Fisher, Stockholm, Sweden) in TBST followed by washes with 2 mM levamisole in NTMT (100 mM NaCl, 10 mM Tris-HCl, pH 9.5, 50 mg MgCl2, and 0.1% Tween-20). Sections were developed in BM purple AP substrate (Roche Diag- nostics Scandinavia) at 37�C. After mounting in glyc- erol,thesectionswerephotographedinaLeicaMZ16F dissection microscope using aDFC300FX cameraand FireCam software (Leica Microsystem). Images were adjusted in Adobe Photoshop CS3 (San Jose, CA, USA) by adjusting the levels and brightness/contrast. Figures were assembled in Adobe Illustrator CS3. Ethical considerations The number of mice used in the study was reduced by allowing one batch of mice (n = 17 Ctrl; n = 12 cKO) for analysis in the elevated plus maze (EPM), the multivariate concentric square field� (MCSF), the social interaction, and the dominance tube test in this order, before being processed for dissection and monoamine analysis by high-pressure liquid chroma- tography (HPLC). Two separate batches of mice were analysed in the Porsolt forced swim test (n = 19 Ctrl; n = 13 cKO) and in an amphetamine provocation set-up (n = 9 Ctrl; n = 9 cKO), respectively. Amphetamine challenge Amphetamine-induced activity was analysed in auto- mated activity boxes, so-called locoboxes (Locobox, Kungsbacka Reglerteknik AB, Kungsbacka, Sweden) that each consists of a plastic cage (55 � 55 � 22 cm) placed inside a ventilated and illuminated (10 lux) cabinet. Inside the locobox, a grid of photo beams (beams spaced by 5 cm) records the movement of the mouse. On the first experimental day, each mouse was allowed to explore the cage for 30 min in order to measure baseline activity, and was thereafter injected with 10 mL/kg saline (i.p.) and allowed back to the locobox for an additional 90 min of monitoring. Twenty-four hours later, the same protocol was used, but instead of saline the mice were injected i.p. with 1.5 mg/kg of amphetamine. The locobox- parameters scored were locomotion, peripheral activ- ity, and corner activity as previously described (16). Locomotion is defined by two beam breaks anywhere in the box; peripheral activity is defined by two beam breaks in the periphery of the box; corner activity is defined by two beam breaks in any of the four corners of the box. Data were analysed by two-way ANOVA by Prism software (GraphPad) (variables: genotype, cKO versus ctrl; time, 30 min for pre-injection and 90 min for post-injection). EPM, MCSF, and social interaction analyses followed by monoamine analysis The behavioural set-ups for the EPM, MCSF, social interaction, and social dominance tests, performed in this order, have been described previously (13). After cervical dislocation, brains were rapidly dissected and mounted into a coronal mouse brain matrix (Ted Pella, 146 K. Nordenankar et al. http://www.genepaint.org Inc., Redding, CA, USA)kept on icefrom which 1-mm slices were prepared. The nucleus accumbens, dorsal striatum, hippocampus, and prefrontal cortex (PFC) from cKO mice and littermate controls were microdis- sected from these slices. Samples were instantly frozen on dryice and kept frozen at �80�C until analysis. After ultrasound homogenization (Sonifier Cell Disruptor B30, Branson Ultrasonics, Danbury, CT, USA) in 0.1 M perchloricacid containing 2.5mM of Na2EDTA and subsequent centrifugation (10,000 rpm, 10 min), the supernatant was collected for analysis. The super- natantwasremoved,andthepelletwashedwithdouble- distilledwaterthreetimes.Amixtureof0.2Maceticacid and0.2Mphosphoricacid(8:2,vol/vol)wasadded,and samples were shaken again for 15 minutes. The eluate was analysed for dopamine (DA), 3,4-dihydroxyphe- nylacetic (DOPAC) and noradrenaline (NA), 3-meth- oxytyramine (3-MT) and serotonin (5-HT) using HPLC with electrochemical detection as previously described (13,34,35). The Porsolt forced swim test The Porsolt swim test represents a model for inter- pretation of animal depression-like behaviour (36,37). Each mouse was placed in a plexiglas cylinder (Ø20 cm) filled with 25 ± 2�C water. The mice were videotaped during two consecutive 12-minute trials with 24 hours in between and scored (Ani- Tracker Software) for total time spent swimming (defined as at least three paws paddling). Statistical analysis A non-parametric Mann–Whitney U test was used for statistical analyses of differences between genotype groups (behaviour and monoamine content) except in the case of behaviour analyses over time when two- way ANOVA or repeated measures two-way ANOVA were implemented. Multiple testing included Bonferroni’s post-hoc comparisons unless otherwise stated. The chi-square test was used for statistical comparison in the elevated plus maze to evaluate the difference in the number of mice entering and not entering the outer open arm. Values in graphs are expressed as mean ± SEM. Results Conditional deletion of Vglut2 expression in the olfactory bulb, cortex, hippocampus, and part of the amygdala complex The Emx1-driven Cre activity in the Emx1IRES-Cre knock-in mouse line was investigated previously by reporter-gene analysis of the R26R strain and shown to be dorsally located in cortical subdivisions of the telencephalon from embryonic day (E) 10.5 and to stay regionally distributed also in the adult telence- phalic area (31). Areas characterized by Emx1-driven Cre activity in the adult included the whole neocortex and the entire hippocampal formation as defined by the subiculum, hippocampus proper, and the dentate gyrus. The olfactory bulb and several, but not all, subpopulations of the amygdala were also characterized by Emx1-driven Cre activity. Cre-active areas included the lateral (L), centrolateral (CL), basolateral (BL), and basomedial (BM) amygdala, while leaving untouched the adjacently located medial (Me) and central (C) amygdaloid nuclei as well as the bed nucleus of stria terminalis (Bst) (the two last-mentioned a part of the so-called extended amygdala). Somewhat weaker activity was detected in the anterior cortical (ACo) amygdala (31). Guided by this previous report, brain sections from Vglut2f/f;Emx1-Cre(tg/wt) cKO mice and littermate Vglut2f/f;Emx1-Cre(wt/wt) control mice, produced as described in ‘Materials and methods’, were analysed by in situ hybridization (ISH) at the adult stage in order to ascertain the targeted deletion of Vglut2. As we previously reported, expression of Vglut2 in the adult telencephalon was found in the retrosplenial group (RSG) and layers III and V/VI (Figure 1E, Q) (13). Expression was also found in the mitral and deep periglomerular cells of the olfactory bulb (Figure 1A, I), much resembling the expression pre- viously reported in the rat olfactory system during embryonal development (14). In accordance with the reported Cre-activity of the Emx1IRES-Cre mouse line (31), Vglut2 mRNA expression was found deleted in all of these telencephalic areas in the cKO brains (Figure 1R, E, B and J). Further, as described before, Vglut2 expression in controls was evident in the sub- iculum, but not in the rest of the hippocampal for- mation (Figure 1Q), and in several subnuclei of the amygdala complex, including the ACo, the BM, and anterior and posteroventral Me nuclei (Figure 1M, O). In the cKO mice, the subicular and BM Vglut2 expression was found absent, again in accordance with the reported Cre activity (Figure 1R, N) (31). However, Vglut2 expression in the ACo appeared reduced only (Figure 1N), in line with the limited Cre activity described in this area (31), while the expression in the Me appeared normal, fitting the apparent lack of Cre activity in these areas (Figure 1N, P) (31). In addition, we addressed Vglut2 expression in all of the remaining brain and found it normal compared to control mice (Figure 1G, H; Table I) (Supplementary Table S1, available online). Thus, in the adult Vglut2f/f;Emx1-Cre(tg/wt) cKO mice, Deletion of Vglut2 expression in the embryonal telencephalon 147 http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc the targeted deletion of Vglut2 is specific to the olfac- tory bulb, cortical subregions, the subiculum, and the BM and ACo areas of the amygdala, regions that all express the Emx1IRES-Cre bicistronic construct. Normal overall histology and distribution of cellular marker genes To verify that the overall brain anatomy was normal in the Vglut2f/f;Emx1-Cre(tg/wt) cKO mice, ISH analysis of one additional glutamatergic marker, Vglut1, and of one marker for inhibitory neurons, the vesicular amino acid transporter (Viaat), was performed. In contrast to the restricted expression of Vglut2 in the telencephalon, Vglut1 is prominently expressed in this area (7,9,11-13,38). Strong Vglut1 expression was found throughout the neocortex and hippocampal formation and also in several subnuclei of the amyg- dala complex (Figure 2A, C), which is in accordance with previous studies. Vglut1 was most prominently expressed in the BL, BM, and Me nuclei of the amygdala. No altered distribution was seen in the cKO brains (Figure 2B, D; and data not shown). Further, expression of Vglut1 in the mid-brain, A B I J K L M N O P Q R C D E F G H Mi Control Vglut2f/f;Emx1-Cre Vglut2 mRNA Vglut2 mRNA Control Vglut2f/f;Emx1-Cre Mi Mi Mi 3.92 3.92 3.92 3.92 RSG RSG RSG BL BL BM BM Aco MePD MePD -1.94 -1.94 RSGRSG Sub -2.80 Sub -2.80 MePV MePV Aco Me Me -1.70 -1.70 -1.22 -1.22 RSG RSG RSG -2.2- -1.22 -2.2- -1.22 -1.34- -1.80 -1.34- -1.80 -3.80-3.40 Gl Gl Gl Gl Figure 1. Specific deletion of Vglut2 in selected forebrain target areas. Floating in situ hybridization on coronal brain (70 mm) sections from control mice and Vglut2f/f;Emx1-Cre cKO mice (A–H) using a DIG-labelled Vglut2 probe. Close-ups as indicated in I–R, which demonstrate that cells expressing Vglut2 mRNA was absent in the mitral cell (Mi) layer and GI layer in the olfactory bulb (I–J). Vglut2 mRNA was also absent in the RSG of the medial cortex in the Vglut2f/f;Emx1-Cre mice (K, L). There is a loss of Vglut2 mRNA in the BMA, in the ACo the mRNA is partially deleted, and the Me amygdala and MePV are unaltered in the Vglut2f/f;Emx1-Cre mice (M–P). Vglut2 mRNA positive cells were present in the Sub in control mice but not in Vglut2f/f;Emx1-Cre cKO mice (Q, R). ACo = anterior cortical amygdaloid area; BL = basolateral amygdaloid nucleus; BM = basomedial amygdaloid nucleus anterior part; cKO = conditional knock-out; DIG = digoxigenin; GI = periglomerular layer; Me = medial amygdaloid nucleus; MePV = posteriorventral medial amygdaloid nucleus; Mi = mitral cell layer; RSG = retrosplenial group; Sub = subiculum; Bregma interval (dorsal, ventral) is shown in lower right corner. 148 K. Nordenankar et al. cerebellum, and pons appeared normal in the cKO brains compared to controls (Figure 2E, F). Viaat expression was also detected, as expected, in inhibi- tory populations and appeared normal in the cKO brain compared to controls (Figure 2G, H). Together, these results showed normal cellular dis- tribution of excitatory and inhibitory populations in the Vglut2f/f;Emx1-Cre(tg/wt) cKO mice, and although this was not quantitative, by ISH analysis, we did not detect differences in expression levels in these areas. Normal basal and amphetamine-induced activity in agreement with unaltered DA levels The behavioural analyses of the previously reported Vglut2f/f;CaMKII-Cre cKO mice revealed a spontaneous hyperactivity which was further accentuated above the levels of the controls when mice were challenged with an acute dose of amphetamine (13). This increased behavioural activation was correlated with increased basal levels of dopamine in the striatum, which we suggested as the underlying cause of the hyperactivity (13), in accordance with the role of dopamine in Table I. Summarized results from in situ hybridization evaluating the presence or not of Vglut2 mRNA in brain structures from three adult Vglut2f/f;Emx1-Cre cKO mice and three control mice. Structure Ctrl cKO Pallium Neocortex + – RSG + – Subiculum + – Hippocampus CA1, CA3, DG – – Septohippocampus – – Ventral endopiriform nucleus + –* Piriform cortex + –* Claustrum + –* Border regions Lateral septum – – Medial septum – – Rostroventral septum – – Endopiriform nucleus – – Lateral amygdala – – BM + –* Me + + ACo + –* Subpallium Olfactory tuberculum + + Striatum – – Ventral pallidum – – Nucleus accumbens ND ND Bed nucleus stria terminalis ND ND Lateral olfactory tract ND ND Olfactory bulb Mitral cell layer + – External plexiform – – Internal plexiform – – Periglomerular layer + –* Granule cell – – Ependymal layer – – The expression for the Emx1-Cre transgene was described previ- ously (Gorski et al. 2002 (31)), and those structures in which Emx1-Cre was there shown to be expressed were analysed for Vglut2 mRNA and listed here. + = expression of Vglut2 mRNA Emx1-Cre transgene; – = no expression; –* = low amounts of expression; cKO = conditional knock-out; DG = dentate gyrus; ND = not determined. A B C D E F G H Me MeBM BM ACo ACo -1.22 Control Vglut2f/f;Emx1-Cre V IA A T m R N A V g lu t1 m R N A -1.22 -1.22 -1.22 -5.80- -6.64-5.80 -1.22- -1.58 -1.22- -1.82 BL BL Figure 2. Verification that the overall gross anatomy is nor- mal in the Vglut2f/f;Emx1-Cre mice compared to control mice. Floating in situ hybridization on coronal brain (70 mm) sections from control and Vglut2f/f;Emx1-Cre cKO mice using a DIG-labelled Viaat (A, B) or Vglut1(C–H) probe. Close-ups show that ACo and BM do not express Vglut1 mRNA, while BL and part of Me express Vglut1 mRNA. ACo = anterior cortical amygdaloid area; BL = basolateral amygdaloid nucleus; BM = basomedial amygda- loid nucleus anterior part; Me = medial amygdaloid nucleus. Bregma interval (dorsal, ventral) is shown in lower right corner. Deletion of Vglut2 expression in the embryonal telencephalon 149 general activational response (39). Caretaker han- dling of the Vglut2f/f;Emx1-Cre(tg/wt) cKO mice now revealed that these mice were calmer than the Vglut2f/f;CaMKII-Cre cKO mice, which we previously had experienced as difficult to handle due to the strong hyperactivity. This observation tentatively suggested that the telencephalic deletion of Vglut2 from embryo development (Vglut2f/f;Emx1-Cre cKO) had a different effect on behaviour than had the postnatal deletion (Vglut2f/f;CaMKII-Cre cKO). By com- paring spontaneous and amphetamine-induced activ- ity between the Vglut2f/f;Emx1-Cre cKO mice and their Baseline activity Locomotion Saline 10 mg/kgA. L o c o m o ti o n ( b e a m b re a k s ) Injection 1000 750 500 250 0 Time (min) -30 -10 0 10 30 50 70 90 Baseline activity Locomotion Amphetamine 1.5 mg/kgB. L o c o m o ti o n ( b e a m b re a k s ) Injection 1000 750 500 250 0 Time (min) -30 -10 0 10 30 50 70 90 Control Vgt2f/f;Emx1-Cre Periferal activity Periferal activity C. L o c o m o ti o n ( b e a m b re a k s ) 1000 750 500 250 0 Time (min) -30 -10 0 10 30 50 70 90 D. L o c o m o ti o n ( b e a m b re a k s ) 1000 750 500 250 0 Time (min) -30 -10 0 10 30 50 70 90 Corner activity Corner activityE. L o c o m o ti o n ( b e a m b re a k s ) 0 100 200 300 L o c o m o ti o n ( b e a m b re a k s ) 0 100 200 300 Time (min) -30 -10 0 10 30 50 70 90 F. Time (min) -30 -10 0 10 30 50 70 90 Figure 3. The Vglut2f/f;Emx1-Cre mice do not show any altered response to amphetamine. The initial response to novel environment (30 min) and overall response after i.p. injection of saline (90 min), 10 mg/kg, in locomotion, periferal activity, and corner activity are unaltered in the Vglut2f/f;Emx1-Cre cKO mice compared to control mice (B, D, F). On day 2, the mice were subjected to the activity boxes for 30 min and were thereafter administered 1.5 mg/kg amphetamine i.p. and were recorded for 90 min (A, C, E). The arrows in the graphs depict the time of saline and amphetamine injection. Data were analysed with two-way ANOVA and showed no significant interactions (effect of genotype). Data are represented as mean ± SEM. cKO = conditional knock-out. 150 K. Nordenankar et al. littermate control mice, no statistically relevant dif- ference in either locomotion, corner activity, or peripheral activity was detected between genotypes either pre- or post-injection by saline or amphetamine (Figure 3A–F) (all statistical data are shown in Sup- plementary Table S2, available online). Further, we did not find any weight differences between either male (ctrl n = 11, 30.4 ± 0.7 g; cKO n = 6, 28.7 ± 0.4 g, P = 0.13) or female mice (n = 10, 22.1 ± 0.8 g; cKO n = 8, 22.5 ± 0.9 g, P = 0.75) of the different genotype groups, indicating normal food intake and activational levels in the cKO mice. Biochemical detection of DA and its metabolite DOPAC as well as noradrenalin, 3-MT, and 5-HT in tissue dissected from the dorsal (caudate putamen) and ventral (nucleus accumbens) striatum did not reveal any differences between the Vglut2f/f;Emx1-Cre(tg/wt) cKO and control mice (Table II). Taken together, these results show that adult mice lacking Vglut2 in selected telencephalic areas from early developmental stages show normal spontaneous and amphetamine-induced activity as well as normal levels of monoamines DA, NA, 5-HT, and their metabolites in the striatum. Decreased avoidance of open areas and time spent in shelter suggest an anxiolytic phenotype Altered social skills, as measured by the social interaction test and the dominance tube test, were part of the behavioural phenotypes described for the Vglut2f/f;CaMKII-Cre cKO (13). By using the same paradigms here, no differences between the Vglut2f/f;Emx1-Cre(tg/wt) cKO and control mice were detected either in the social interaction test (P = 0.85) or in the dominance tube test (P = 0.58) (Figure 4A, B). Also, no difference between genotype groups could be discerned in the Porsolt forced swim test, a model for despair-like behaviour (trial 1, P = 0.86; trial 2 P = 0.54) (Figure 4C), which previ- ously revealed an altered response in the Vglut2f/f; CaMKII-Cre cKO mice (13). Behavioural analysis of relevance to anxiety in humans include an apparatus which takes into advantage the rodent’s preference for familiar, dark, and/or enclosed areas (40). The EPM, which allows exploration of open versus enclosed areas is perhaps the most commonly used such method. The MCSF, which contains multiple chal- lenges including both an open field and a dark, sheltered space, as well as challenges related to risk-assessment and risk-taking, is another valuable paradigm which we have used before (24,41,42). During a 10-minute trial, Vglut2f/f;Emx1-Cre cKO and control mice were analysed in the EPM. The number of entries (frequency) into each area; i.e. the centre, the closed, and the inner and outer segments of the open arm were scored (Figure 4D), as was the time spent (duration) in each of these compartments (Figure 4D). No differences in either total activity (the sum of all frequencies) in the maze (P = 0.84) or in any other parameter were identified (centre fre- quency, P = 0.83; closed arm frequency, P = 0.60; inner arm frequency, P = 0.57; outer arm frequency, Table II. Levels of monoamines and dopamine metabolites (ng/g of wet tissue) of Vglut2f/f;Emx1-Cre cKO (n = 12) and control (n = 18) mice. The data show no statistically significant alterations between control and cKO mice. Data are presented as mean ± SEM. Brain region Metabolite Ctrl Vg2f/f;Emx1-Cre P value Nucleus accumbens Dopamine 0.0129 ± 9.1E-04 0.0122 ± 9.5E-04 0.21 DOPAC 0.0053 ± 3.9E-04 0.0049 ± 5.7E-04 0.48 DOPAC/DA 0.4784 ± 3.6E-02 0.4708 ± 4.6E-02 0.99 NA 0.0015 ± 2.1E-04 0.0015 ± 3.1E-04 0.82 3-MT 0.0032 ± 2.7E-04 0.0025 ± 2.9E-04 0.26 5-HT 0.0040 ± 3.1E-04 0.0030 ± 3.8E-04 0.15 Caudatus putamen Dopamine 0.0197 ± 1.4E-03 0.0200 ± 2.2E-03 0.08 DOPAC 0.0059 ± 5.2E-04 0.0066 ± 7.0E-04 0.51 DOPAC/DA 0.3386 ± 4.7E-02 0.2958 ± 2.1E-02 0.47 NA 0.0004 ± 8.0E-05 0.0003 ± 4.7E-05 0.51 3-MT 0.0038 ± 5.0E-04 0.0045 ± 4.8E-04 0.36 5-HT 0.0012 ± 2.2E-04 0.0015 ± 2.1E-04 0.24 P < 0.05 (Mann–Whitney U test). Nucleus accumbens corresponds to the ventral striatum; Caudatus putamen to the dorsal striatum. 3-MT = 3-methoxytyramine; 5-HT = 5-hydroxytryptamine; cKO, conditional knock-out; DOPAC = 3,4-dihydroxypheneylacetic acid; NA = noradrenalin. Deletion of Vglut2 expression in the embryonal telencephalon 151 http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc Social interaction Total activity Closed arm Total activity Central circle Central circle Central field Dark corner Outer inner arm Outer open arm Not entering Entering Dominance tube test Porsolt swin test Elevated plus maze * * * * * Multivarite concentric square field A. B. C. D u ra ti o n ( s ) 100 80 40 60 20 0 D. E. F re q u e n c y ( n u m b e r o f e n tr ie s ) 80 40 60 20 0 D u ra ti o n ( s ) D u ra ti o n ( s ) 500 400 300 200 100 0 D u ra ti o n ( s ) 50 40 30 20 10 0 N u m b e r o f e n tr ie s i n o u te r o p e n a rm 0 5 10 15 20 0 5 10 15 20 D u ra ti o n ( s ) 0 50 100 150 200 N u m b e r o f w in s 0 0.5 1.0 1.5 0 5 10 15 Im m o b il e ( s ) 150 100 50 0 F re q u e n c y ( n u m b e r o f e n tr ie s ) F re q u e n c y ( n u m b e r o f e n tr ie s ) 150 100 50 0 Trial 1 Trial 2 Control Vgt2f/f;Emx1-Cre Figure 4. No social deficits or altered despair-like behaviour, but decreased avoidance of open areas and time spent sheltered. Social behaviour analysis on adult Vglut2f/f;Emx1-Cre cKO mice and control littermates (A, B). The total time spent interacting during a 10-min social interaction session shows no alteration in the Vglut2f/f;Emx1-Cre cKO mice compared to control mice (A). The number of wins in the social dominance tube test shows that the Vglut2f/f;Emx1-Cre cKO mice do not display any altered dominance compared to control (B). The Vglut2f/f;Emx1-Cre mice spent equal time swimming during two 12 min swimming sessions separated 24 h apart in the Porsolt swim test (C). The total activity and the duration in the threedifferentareasintheelevatedplusmazeshownosignificantdifferencesbetweengenotypes.Thenumberoftotalentriesintheouteropenarm is statistically different between the Vglut2f/f;Emx1-Cre cKO mice compared to control mice (*P < 0.05, chi-square test) (D). The total activity as measured in the multivariate concentric square field (MCSF) shows no altered behaviour for the Vglut2f/f;Emx1-Cre cKO mice compared to control mice.ThefrequencyinthecentralcircleanddurationinthecentralcircleaswellasincentralfieldaresignificantlyincreasedfortheVglut2f/f;Emx1-Cre mice compared to control mice; the duration in the dark corner is significantly decreased in the Vglut2f/f;Emx1-Cre cKO mice compared to control mice (E). Values represent mean ± SEM. * P < 0.05 compared to control littermates. cKO = conditional knock-out. P = 0.39; centre time, P = 0.20; closed arm time, P = 0.77; inner open arm time, P = 0.28; and outer open arm time; P = 0.65). However, when analysing the number of mice that entered the outer open arm, we found that significantly more cKO than control mice actually visited this exposed area (chi-square, P = 0.010) (Figure 4D). To analyse this putatively anxi- olytic phenotype further, we turned to the MCSF paradigm (all statistical data are shown in Supple- mentary Table S3, available online). While displaying the same overall activational level as the controls (Figure 4E), the Vglut2f/f;Emx1-Cre(tg/wt) cKO mice showed a significantly decreased avoidance of the open areas as displayed by higher frequency of visits inthecentralcircleandthetimespentthere(Figure4E). ThecKOmicealsodisplayeddecreasedshelter-seeking in the dark room and increased time in the central field. Decreasedavoidanceofopenareasandofthedarkroom were previously identified in the Vglut2f/f;CaMKII-Cre cKO mice which also showed a general hyperactivity and increased risk-assessment and exploratory behav- iour. Compared to the Vglut2f/f;CaMKII-Cre cKO mice, the Vglut2f/f;Emx1-Cre cKO mice thus show a milder behavioural phenotype, but one which is more specif- ically centred around anxiolysis instead of strong hyperactivity in several different aspects. Taken together, the behavioural alterations identified in the EPM and the MCSF show that the Vglut2f/f;Emx1-Cre cKO mice have an anxiolytic phenotype. Discussion Contrary to the strong behavioural phenotype observed when Vglut2 was gene-targeted in the forebrain from postnatal week 3 and onwards (Vglut2f/f;CamKII-Cre mouse line) (13), the embryonic onset of deletion used in the current study (the Vglut2f/f;Emx1-Cre mouse line) produced a milder beha- vioural phenotype focused around anxiolysis. As Vglut2 is broadly expressed in the embryonic mouse brain, including within the dorsal telencephalon (16,17), the embryonal gene targeting in the current study is likely to affect brain development and adult function profoundly differently than a targeting event occurring from 3 weeks of age. Further, the earlier temporal onset of Vglut2 deletion in the Vglut2f/f;Emx1-Cre mouse line (E10.5 onwards) com- pared to the Vglut2f/f;CamKII-Cre mouse line (P20 onwards) might lead to the milder behavioural phe- notype due to compensations made possible during embryogenesis, but which fail to rescue functions in the postnatal life. In addition to developmental dif- ferences between the Vglut2f/f;CamKII-Cre and the Vglut2f/f;Emx1-Cre transgenic mouse lines, an important factor that may contribute to the identified permutations is the genetic background of the mice. Although both kept on a hybrid of C57/BL6J and Sv129, the exact quantity of each contributor is difficult to ascertain. However, as the cKO mice of each line are compared to littermate control mice of the identical genetic background, the impact of genetic background for the overall interpretation of the result is limited. Importantly, although the spatial extent of gene targeting appeared the same in the neocortex, sub- iculum, and olfactory bulb in the cKO mice of both the Vglut2f/f;Emx1-Cre and Vglut2f/f;CamKII-Cre mouse lines, Vglut2 expression was somewhat differentially targeted within the amygdaloid subnuclei. In the Vglut2f/f;CamKII-Cre cKO mice, all amygdaloid expres- sion of Vglut2 was lacking as identified by our previous ISH analysis (13). In the Vglut2f/f;Emx1-Cre cKO mice, on the other hand, only the Vglut2 expression in the BM amygdala was completely lacking, while expres- sion in the ACo nucleus was merely blunted and the Me amygdala showed normal Vglut2 expression. This observation shows that the spatial activity within the amygdala differs between the Emx1-Cre and the Cam- KII-Cre transgenes. The amygdaloid complex, con- sisting of a series of heterogeneous subnuclei, is known to be important for aspects of both fear and anxious behaviour. Anxiety, experienced as unease, dread, apprehension, and similar, is a negative- valenced emotion characterized by sustained hyperarousal in response to uncertainty (42-44). Experienced by all individuals, anxiety serves to guide decision-making by contributing to evaluation of risk and need for defence or avoidance. When anxiety becomes excessive or pathological, however, it may lead up to the substantial group of anxiety disorders that include generalized anxiety disorder and obsessive-compulsive disorder (42,44). A vast num- ber of studies have shown that patients with various kinds of anxiety disorder show amygdala hyperactivity in response to anxiogenic stimuli, leading to the view of amygdala hyperfunction as a key component of human anxiety disorder (45-49). The contribution of specific amygdaloid subnuclei is not firmly estab- lished yet, but both inhibitory and excitatory amyg- daloid nuclei are implicated in the neurocircuitry of anxiety. In the mouse, the excitatory subnuclei express either Vglut1 or Vglut2, or both, as shown above. The interconnectivity between the amygdaloid nuclei has been investigated thoroughly (described in detail in (50)). The lateral (L; Vglut1-expressing) and the Me (Vglut1/Vglut2-expressing) nuclei send reciprocal projections to the basal (B) and accessory basal (BA) amygdaloid nuclei, which also receive an excitatory drive from the subiculum (Vglut1/Vglut2- expressing). Excitatory BL amygdala (Vglut1) and Deletion of Vglut2 expression in the embryonal telencephalon 153 http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc local inhibitory projections gate the activity of the inhibitory nucleus central amygdala which in turn projects out from the amygdala to brain-stem, basal forebrain, and hypothalamus regions that control autonomic, hormonal, and behavioural responses to emotional situations. Additional connectivity between the above-mentioned amygdaloid nuclei is also sub- stantially involved in the regulation of emotional responses, which were only briefly summarized here for an overview of Vglut1 and Vglut2 expression. Although a Vglut2-expressing nucleus, the Me amyg- dala was not targeted in the Vglut2f/f;Emx1-Cre cKO mice due to the lack of Emx-Cre-activity in this particular nucleus; thus the anxiolytic phenotype of these cKO mice cannot be attributed to a loss of excitatory drive from this specific subnucleus. On the other hand, the Me nucleus was Vglut2-targeted in the Vglut2f/f;CamKII-Cre cKO mice, possibly explain- ing the more profound anxiolytic phenotype in these mice, which included increased risk-taking. In the Vglut2f/f;Emx1-Cre cKO mice, Vglut2 was deleted in the BM amygdala and partly in the ACo. Further studies would be required to reveal if the loss of Vglut2 in these particular areas contributes to the observed behavioural phenotypes. Importantly, based on the rather broad deletion of Vglut2 in the entire telen- cephalon during embryonal development, it is con- ceivable that the cause of the anxiolytic phenotype is independent on the restricted targeting of Vglut2 in the BMA and ACo. For example, as mentioned above, the importance of the subiculum, which expresses both Vglut1 and Vglut2 and which we show is lacking Vglut2 in the cKO mice (both in the Vglut2f/f;CamKII-Cre and Vglut2f/f;Emx1-Cre mouse lines), should not be neglected. The subiculum inner- vates the B/BA amygdaloid nuclei, and loss of Vglut2 in this hippocampal area may substantially decrease the glutamatergic drive into the amygdala, altering the final balance of output from the CeA so that the level of anxiety is measurably decreased. Hippocampus function in the cKO mice of a similar Vglut2f/f;Emx1-Cre mouse line was in fact previously shown to be char- acterized by reduced evoked glutamatergic transmis- sion and release probability in the CA3-CA1 region (51), a feature that might also contribute to the anxiolytic phenotype. Further addressing the functional roles ascribed to the amygdaloid nuclei expressing Vglut2, the BM, M, and ACo amygdala nuclei have all been shown to mediate feeding behaviour via extensive connectivity directly with e.g. the hypothalamus (52,53). No alter- ation in body weights were observed in our cKO mice, an observation which, taken together with the normal extent of spontaneous activity, indicates a normal amount of food intake. In summary, the main findings of the current study indicate that expression of Vglut2 in the dorsal telen- cephalic area from mid-gestation is not of major importance for establishing the general activational level, responsiveness to the psychostimulant amphetamine, or for sociability, behaviours that all are affected when Vglut2 is removed in the same areas during adolescence. However, expression of Vglut2 in the dorsal telencephalic area from mid-gestation is shown to be involved in the regulation of anxiety, possibly by providing excitatory input into the amygdala or by ascertaining a balanced intra- amygdaloid connectivity. Given this restricted behavioural phenotype, the Vglut2f/f;Emx1-Cre mouse line might be considered a useful tool for further analysis of the neurocircuitry and neurobiology of anxiety. Acknowledgements The authors thank Professor Klas Kullander, Uppsala University, for constructive input during the initiation of this study; Professor Kevin Jones, University of Colorado-Boulder, and Professor Rudiger Klein, Max-Planck Institute for Neurobiology, for providing the Emx-Cre mouse line. We thank Dr Carolina Birgner, Uppsala University, for performing the HPLC analysis, and Drs Daniel Andersson and Erik Stuber, both at Gothenburg University, for pro- viding technical expertise in HPLC analysis and behaviour analysis, respectively. Funding: This work was supported by grants from the Swedish Medical Research Council (2007-5742, 2011- 4747), Uppsala University, the Swedish Brain Foundation, the Hållsten Research Foundation, and the foundations of Åke Wiberg and Åhlén. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. References 1. Nakagawa T, Kaneko S. SLC1 glutamate transporters and diseases: psychiatric diseases and pathological pain. Curr Mol Pharmacol. 2013;6:66–73. 2. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizo- phrenia: from basic research to clinical practice. Curr Opin Psychiatry. 2012;25:96–102. 3. McCullumsmith RE, Hammond J, Funk A, Meador- Woodruff JH. Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia. Curr Pharm Biotechnol. 2012;13:1535–42. 4. Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci. 2013;13:583–609. 154 K. Nordenankar et al. http://www.ncbi.nlm.nih.gov/pubmed/23876150?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/23876150?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/22297716?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/22297716?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/22283761?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/22283761?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/22389180?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/22389180?dopt=Abstract 5. Bellocchio EE, Reimer RJ, Fremeau RT, Edwards RH. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science. 2000;289:957–60. 6. Fremeau RT, Burman J, Qureshi T, Tran CH, Proctor J, Johnson J, et al. The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate. Proc Natl Acad Sci USA. 2002;99:14488–93. 7. Fremeau RT Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, et al. The expression of vesicular glutamate transporters defines two classes of excitatory syn- apse. Neuron. 2001;31:247–60. 8. Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C, et al. The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neuron. J Neurosci. 2001;21:RC181. 9. Kaneko T, Fujiyama F. Complementary distribution of vesic- ular glutamate transporters in the central nervous system. Neurosci Res. 2002;42:243–50. 10. Takamori S, Rhee JS, Rosenmund C, Jahn R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature. 2000;407:189–94. 11. Hisano S, Hoshi K, Ikeda Y, Maruyama D, Kanemoto M, Ichijo H, et al. Regional expression of a gene encoding a neuron-specific Na(+)-dependent inorganic phosphate cotransporter (DNPI) in the rat forebrain. Brain Res Mol Brain Res. 2000;83:34–43. 12. Nakamura K, Hioki H, Fujiyama F, Kaneko T. Postnatal changes of vesicular glutamate transporter (VGluT)1 and VGluT2 immunoreactivities and their colocalization in the mouse forebrain. J Comp Neurol. 2005;492:263–88. 13. Wallen-Mackenzie A, Nordenankar K, Fejgin K, Lagerstrom MC, Emilsson L, Fredriksson R, et al. Restricted cortical and amygdaloid removal of vesicular glutamate trans- porter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function. J Neurosci. 2009;29:2238–51. 14. Ohmomo H, Ina A, Yoshida S, Shutoh F, Ueda S, Hisano S. Postnatal changes in expression of vesicular glutamate trans- porters in the main olfactory bulb of the rat. Neuroscience. 2009;160:419–26. 15. Poulin JF, Castonguay-Lebel Z, Laforest S, Drolet G. Enkephalin co-expression with classic neurotransmitters in the amygdaloid complex of the rat. J Comp Neurol. 2008; 506:943–59. 16. Birgner C, Nordenankar K, Lundblad M, Mendez JA, Smith C, le Greves M, et al. VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation. Proc Natl Acad Sci USA. 2010;107:389–94. 17. Nordenankar K, Smith-Anttila CJ, Schweizer N, Viereckel T, Birgner C, Mejia-Toiber J, et al. Increased hippocampal excitability and impaired spatial memory function in mice lacking VGLUT2 selectively in neurons defined by tyrosine hydroxylase promoter activity. Brain Struct Funct. 2014;Epub ahead of print. 18. Fremeau RT Jr, Voglmaier S, Seal RP, Edwards RH. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci. 2004;27:98–103. 19. Boulland J-L, Qureshi T, Seal RP, Rafiki A, Gundersen V, Bergersen LH, et al. Expression of the vesicular glutamate transporters during development indicates the widespread corelease of multiple neurotransmitters. J Comp Neurol. 2004;480:264–80. 20. Gras C, Vinatier J, Amilhon B, Guerci A, Christov C, Ravassard P, et al. Developmentally regulated expression of VGLUT3 during early post-natal life. Neuropharmacology. 2005;49:901–11. 21. Garcia-Garcia AL, Elizalde N, Matrov D, Harro J, Wojcik SM, Venzala E, et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry. 2009;66:275–82. 22. Tordera RM, Totterdell S, Wojcik SM, Brose N, Elizalde N, Lasheras B, et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci. 2007;25:281–90. 23. Moechars D, Weston MC, Leo S, Callaerts-Vegh Z, Goris I, Daneels G, et al. Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain. J Neurosci. 2006;26:12055–66. 24. Wallen-Mackenzie A, Gezelius H, Thoby-Brisson M, Nygard A, Enjin A, Fujiyama F, et al. Vesicular glutamate transporter 2 is required for central respiratory rhythm gen- eration but not for locomotor central pattern generation. J Neurosci. 2006;26:12294–307. 25. Wallen-Mackenzie A, Wootz H, Englund H. Genetic inacti- vation of the vesicular glutamate transporter 2 (VGLUT2) in the mouse: what have we learnt about functional glutamatergic neurotransmission? Ups J Med Sci. 2010;115:11–20. 26. El Mestikawy S, Wallen-Mackenzie A, Fortin GM, Descarries L, Trudeau LE. From glutamate co-release to vesicular synergy: vesicular glutamate transporters. Nat Rev Neurosci. 2011;12:204–16. 27. Alsio J, Nordenankar K, Arvidsson E, Birgner C, Mahmoudi S, Halbout B, et al. Enhanced sucrose and cocaine self-administration and cue-induced drug seeking after loss of VGLUT2 in midbrain dopamine neurons in mice. J Neurosci. 2011;31:12593–603. 28. Hnasko TS, Chuhma N, Zhang H, Goh GY, Sulzer D, Palmiter RD, et al. Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo. Neuron. 2010;65:643–56. 29. Fortin GM, Bourque MJ, Mendez JA, Leo D, Nordenankar K, Birgner C, et al. Glutamate corelease pro- motes growth and survival of midbrain dopamine neurons. J Neurosci. 2012;32:17477–91. 30. Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V, et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron. 1999;24:401–14. 31. Gorski JA, Talley T, Qiu M, Puelles L, Rubenstein JL, Jones KR. Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J Neurosci. 2002;22:6309–14. 32. Crusio WE. Flanking gene and genetic background problems in genetically manipulated mice. Biol Psychiatry. 2004;56: 381–5. 33. Wolfer DP, Crusio WE, Lipp HP. Knockout mice: simple solutions to the problems of genetic background and flanking genes. Trends Neurosci. 2002;25:336–40. 34. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem. 2010;112:1465–76. 35. Elverfors A, Pileblad E, Lagerkvist S, Bergquist F, Jonason J, Nissbrandt H. 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra. J Neurochem. 1997; 69:1684–92. Deletion of Vglut2 expression in the embryonal telencephalon 155 http://www.ncbi.nlm.nih.gov/pubmed/10938000?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/10938000?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12388773?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12388773?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11502256?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11502256?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11502256?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11985876?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11985876?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11001057?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11001057?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11001057?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11072093?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11072093?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11072093?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16217795?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16217795?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16217795?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16217795?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19228977?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19228977?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19228977?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19228977?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19264112?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19264112?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18085591?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18085591?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20018672?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20018672?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/24802380?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/24802380?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/24802380?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/24802380?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15102489?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15102489?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15515175?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15515175?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15515175?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16182324?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16182324?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19409534?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19409534?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19409534?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17241289?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17241289?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17241289?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17241289?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17108179?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17108179?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17122055?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17122055?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17122055?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20187846?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20187846?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20187846?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20187846?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21415847?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21415847?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21880920?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21880920?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21880920?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20223200?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20223200?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/23197738?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/23197738?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/10571233?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/10571233?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12151506?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12151506?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12151506?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15364034?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15364034?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12079755?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12079755?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12079755?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20050978?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20050978?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20050978?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20050978?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20050978?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/9326297?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/9326297?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/9326297?dopt=Abstract 36. Porsolt RD, Brossard G, Hautbois C, Roux S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci. 2001; Chapter 8:Unit 8. 10A. 37. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry. 2004;9: 326–57. 38. Stornetta RL, Sevigny CP, Schreihofer AM, Rosin DL, Guyenet PG. Vesicular glutamate transporter DNPI/ VGLUT2 is expressed by both C1 adrenergic and nonami- nergic presympathetic vasomotor neurons of the rat medulla. J Comp Neurol. 2002;444:207–20. 39. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev. 1991; 71:155–234. 40. Engin E, Treit D. The effects of intra-cerebral drug infusions on animals’ unconditioned fear reactions: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1399– 419. 41. Meyerson BJ, Augustsson H, Berg M, Roman E. The concentric square field: a multivariate test arena for analysis of explorative strategies. Behav Brain Res. 2006; 168:100–13. 42. Sylvers P, Lilienfeld SO, LaPrairie JL. Differences between trait fear and trait anxiety: implications for psychopathology. Clin Psychol Rev. 2011;31:122–37. 43. McNaughton N, Corr PJ. A two-dimensional neuropsychol- ogy of defense: fear/anxiety and defensive distance. Neurosci Biobehav Rev. 2004;28:285–305. 44. Graham BM, Milad MR. The study of fear extinction: impli- cations for anxiety disorders. Am J Psychiatry. 2011;168: 1255–65. 45. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476–88. 46. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, et al. Common changes in cerebral blood flow in patients with social phobia treated with citalo- pram or cognitive-behavioral therapy. Arch Gen Psychiatry. 2002;59:425–33. 47. Sah P, Faber ES, Lopez De Armentia M, Power J. The amygdaloid complex: anatomy and physiology. Physiol Rev. 2003;83:803–34. 48. BlairK,ShaywitzJ,SmithBW,RhodesR,GeraciM,JonesM,et al. Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry. 2008;165:1193–202. 49. Bruhl AB, Rufer M, Delsignore A, Kaffenberger T, Jancke L, Herwig U. Neural correlates of altered general emotion processing in social anxiety disorder. Brain Res. 2011;1378: 72–83. 50. Forster GL, Novick AM, Scholl JL, Watt MJ. The role of the amygdala in anxiety disorders. In Ferry B, editor. The amygdala—a discrete multitasking manager. 2012. doi: 10.5772/50323. 51. He H, Mahnke AH, Doyle S, Fan N, Wang CC, Hall BJ, et al. Neurodevelopmental role for VGLUT2 in pyramidal neuron plasticity, dendritic refinement, and in spatial learning. J Neurosci. 2012;32:15886–901. 52. Price JL. Comparative aspects of amygdala connectivity. Ann N Y Acad Sci. 2003;985:50–8. 53. Canteras NS, Simerly RB, Swanson LW. Organization of projections from the medial nucleus of the amygdala: a PHAL study in the rat. J Comp Neurol. 1995;360:213–45. Supplementary material available online Supplementary Table S1. Supplementary Table S2. Supplementary Table S3. 156 K. Nordenankar et al. http://www.ncbi.nlm.nih.gov/pubmed/14743184?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/14743184?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/14743184?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11840475?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11840475?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11840475?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/1986388?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/1986388?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18495312?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18495312?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18495312?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16356558?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16356558?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/16356558?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20817337?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/20817337?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15225972?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/15225972?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21865528?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21865528?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17898336?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17898336?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/17898336?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11982446?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11982446?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/11982446?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12843409?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12843409?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18483136?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18483136?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/18483136?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21215728?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/21215728?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/23136427?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/23136427?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/12724147?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/8522644?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/8522644?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/8522644?dopt=Abstract http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc http://informahealthcare.com/doi/suppl/10.3109/03009734.2015.1032454/suppl_file/10.3109/03009734.2015.1032454_suppl.doc Abstract Introduction Material and methods Animals Generation of Vglut2f/f;Emx1-Cre mice Tissue sectioning and RNA probes In situ hybridization on free-floating sections Ethical considerations Amphetamine challenge EPM, MCSF, and social interaction analyses followed by monoamine analysis The Porsolt forced swim test Statistical analysis Results Conditional deletion of Vglut2 expression in the olfactory bulb, cortex, hippocampus, and part of the amygdala complex Normal overall histology and distribution of cellular marker genes Normal basal and amphetamine-induced activity in agreement with unaltered DA levels Decreased avoidance of open areas and time spent in shelter suggest an anxiolytic phenotype Discussion Acknowledgements Declaration of interest References